UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 29, 2025
Nuveen Churchill Private Capital Income Fund
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | |
Delaware | | 000-56412 | | 88-6187397 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | | | | | | |
375 Park Avenue, 9th Floor, New York, NY | | 10152 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (212) 478-9200
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | | | |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | | | |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | | | | |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
None | | N/A | | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
Net Asset Value
In accordance with Nuveen Churchill Private Capital Income Fund’s (the “Fund”) valuation policy, the Fund intends to sell its shares on the first business day of each month at an offering price that it believes reflects the net asset value (“NAV”) per share at the end of the preceding month. The table below sets forth the public offering prices for the Fund’s Class I, Class S, and Class D shares of beneficial interest, which was approximately equal to their respective NAV per share.
| | | | | | | | | | | | | | | | | | | | |
| | NAV as of December 31, 2024 |
Class I shares | | $24.80 |
Class S shares | | $24.74 |
Class D shares | | $24.79 |
As of December 31, 2024, the Fund’s aggregate NAV was approximately $826.0 million, the fair value of its investment portfolio was $1.7 billion, and it had $909.5 million in secured borrowings outstanding.
As of December 31, 2024, the Fund's Class I, Class S, and Class D shares of beneficial interest generated the following returns:1
| | | | | | | | | | | | | | | | | | | | |
| Inception date | 1-Month | 3-Month | Year to Date | 1-Year | Since Inception |
Class I Shares | March 30, 2022 | 0.93% | 2.73% | 11.22% | 11.22% | 11.38% |
Class S Shares | October 2, 2023 | 0.86% | 2.48% | 10.23% | 10.23% | 11.06% |
Class D Shares | October 2, 2023 | 0.91% | 2.67% | 10.91% | 10.91% | 11.90% |
Distributions
On January 29, 2025, the Fund’s board of trustees (the “Board”) declared regular distributions for each class of its shares of beneficial interests in the amount per share set forth below. The regular distributions are payable to shareholders of record as of January 31, 2025 and the payment date is on or about February 28, 2025.
| | | | | | | | | | | |
| Gross Regular Distributions | Shareholder Servicing Fee | Net Total Distributions |
Class I shares | $0.200 | $— | $0.200 |
Class S shares | $0.200 | $0.017 | $0.183 |
Class D shares | $0.200 | $0.005 | $0.195 |
Portfolio Update
As of December 31, 2024, the Fund had debt investments and equity investments in 275 portfolio companies with an aggregate of $1.7 billion (at cost) in investments and an average position size of 0.36%.2 As of December 31, 2024, the Fund’s investments consisted of 92.70% first-lien debt investments, 3.08% second-lien debt investments, 3.05% mezzanine debt investments, and 1.17% equity investments (at fair value). As of December 31, 2024, on a fair value basis, 94.66% of the Fund’s debt investments bear interest at a floating rate and 5.34% of the Fund’s debt investments bear a fixed rate. As of December 31, 2024, the weighted average yield on the debt and income producing investments at fair value was 9.69%.3
As of December 31, 2024, our portfolio companies had a weighted average reported EBITDA (including all private debt investments and excluding quoted assets) of $81.8 million. Including all quoted assets as of December 31, 2024, our portfolio companies had a weighted average reported EBITDA of $226.3 million. EBITDA amounts are derived from the most recently available portfolio company financial statements and are weighted based on the fair market value of each respective investment as of its most recent valuation. As of December 31, 2024, our portfolio companies had a weighted average loan-to-value of 40.20%.4
1 This table reflects the effect of the supplemental distribution that was declared on December 26, 2024 to shareholders of record as of December 31, 2024 and supersedes the Form 8-K filed on December 27, 2024, which inadvertently included the effect of such supplemental distribution as of November 30, 2024.
2 Average position size is calculated as a percentage of the total fair value of the Fund's investment portfolio.
3 The weighted average yield of the Fund's debt and income producing securities is not the same as a return on investment for the Fund's shareholders, but rather relates to the Fund's investment portfolio and is calculated before the payment of all of the Fund's and its subsidiary’s fees and expenses. The weighted average yield was computed using the effective interest rates as of each respective date, including accretion of original issue discount, but excluding investments on non-accrual status. Weighted average yield inclusive of debt and income producing investments on non-accrual status at fair value was 9.67%. There can be no assurance that the weighted average yield will remain at its current level.
4 Weighted average loan-to-value represents the net ratio of loan-to-value for each portfolio company, weighted based on the fair value of total applicable private debt investments. Loan-to-value is calculated as the current total net debt through each respective loan tranche divided by the estimated enterprise value of the portfolio company as of the most recently available financial information. Includes all private debt investments for which fair value is determined by Churchill PCIF Advisor LLC (the "Adviser"), in its capacity as the Board's valuation designee (the “Valuation Designee”), and excludes quoted assets, as well as investments that the Adviser has assigned an internal risk rating of 8 or higher, investments on non-accrual, and portfolio companies with net leverage of 15x or greater. Amounts are weighted on fair market value of each respective investment. Amounts were derived from the most recently available portfolio company financial statements, have not been independently verified by the Fund, and may reflect a normalized or adjusted amount. Accordingly, the Fund makes no representation or warranty in respect of this information.
The industry composition of the Fund’s portfolio as a percentage of fair value as of December 31, 2024 was as follows:
| | | | | | | | |
Industry | | December 31, 2024 |
Aerospace & Defense | | 1.93 | % |
Automotive | | 1.72 | % |
Banking, Finance, Insurance & Real Estate | | 3.76 | % |
| | |
Beverage, Food & Tobacco | | 5.40 | % |
Capital Equipment | | 7.45 | % |
Chemicals, Plastics & Rubber | | 2.64 | % |
Construction & Building | | 7.11 | % |
Consumer Goods: Durable | | 1.27 | % |
Consumer Goods: Non-durable | | 3.56 | % |
Containers, Packaging & Glass | | 1.14 | % |
Energy: Electricity | | 1.60 | % |
Energy: Oil & Gas | | 0.57 | % |
Environmental Industries | | 4.38 | % |
Healthcare & Pharmaceuticals | | 12.14 | % |
High Tech Industries | | 8.49 | % |
Hotel, Gaming & Leisure | | 0.38 | % |
Media: Advertising, Printing & Publishing | | 1.03 | % |
Media: Broadcasting & Subscription | | 0.33 | % |
Media: Diversified & Production | | 0.31 | % |
Metals and Mining | | 0.16 | % |
Retail | | 0.15 | % |
Services: Business | | 16.37 | % |
Services: Consumer | | 5.88 | % |
Sovereign & Public Finance | | 0.55 | % |
Telecommunications | | 2.50 | % |
Transportation: Cargo | | 2.02 | % |
Transportation: Consumer | | 1.13 | % |
Utilities: Electric | | 2.80 | % |
Utilities: Water | | 0.59 | % |
Wholesale | | 2.64 | % |
Total | | 100.00 | % |
The Fund's top ten portfolio companies as of December 31, 2024 were as follows:
| | | | | | | | | | | | | | |
Portfolio Company | | Industry | | % of Fair Value of Investments |
Kenco PPC Buyer LLC | | Transportation: Cargo | | 1.27% |
PAG Holding Corp. (Precision Aviation Group) | | Aerospace & Defense | | 1.18% |
Motion & Control Enterprises LLC | | Capital Equipment | | 1.18% |
VMG Holdings LLC (VMG Health) | | Healthcare & Pharmaceuticals | | 1.18% |
Impact Parent Corporation (Impact Environmental Group) | | Environmental Industries | | 1.16% |
Matador US Buyer, LLC (Insulation Technology Group) | | Energy: Electricity | | 1.16% |
ISG Enterprises, LLC (Industrial Service Group) | | Wholesale | | 1.15% |
Olympus US Bidco LLC (Phaidon International) | | Services: Business | | 1.14% |
Transit Buyer, LLC (Propark Mobility) | | Services: Business | | 1.09% |
Soliant Lower Intermediate, LLC | | Services: Business | | 1.09% |
Past performance is not necessarily indicative of future performance, and there can be no assurance that the Fund will achieve comparable investment results, or that any targeted returns will be met.
The information presented above is based on the determination of the Valuation Designee as of December 31, 2024. The valuation process is subject to the review and oversight by the Board to determine that the Valuation Designee selected and consistently applied the appropriate valuation methodologies in connection with the Valuation Designee's determination of the fair value of the Fund's portfolio securities. Consequently, the data set forth in the Fund’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 may differ from this information, and any such differences may be material. In addition, the information presented above does not include all of the information regarding our financial condition and results of operations that may be important to investors. As a result, investors are cautioned not to place undue reliance on the information presented above. Neither PricewaterhouseCoopers LLP, the Fund’s independent registered public accounting firm, nor any other independent accountants, have audited, reviewed, compiled or performed procedures with respect to the financial data contained herein. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any form of assurance with respect thereto and assumes no responsibility for, and disclaims any association with, this information.
Teachers Insurance and Annuity Association of America, the ultimate parent company of the Fund's investment adviser, may, from time to time, sell a portion of its Class I shares of beneficial interest in the Fund to unaffiliated investors in reliance upon an exemption from registration under the Securities Act of 1933, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | |
| Nuveen Churchill Private Capital Income Fund |
| | |
Date: January 29, 2025 | By: | | /s/ Kenneth J. Kencel |
| | | Kenneth J. Kencel Chief Executive Officer and President |